The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
== Background == In 1994, with record labels trying to capitalize on the popularity of grunge and alternative rock bands like Nirvana, Pearl Jam, and Soundgarden, Local H caught the attention of Polydor Records, which was then in the process of merging with Island Records. Island released the band's debut studio album, Ham Fisted, the following year, but it sold below expectations and Island pressured the band's A&R rep, Joe Bosso, to drop them. Instead, Bosso pushed them into quickly recording a follow-up before Island could cancel their contract. Ahead of the release of As Good as Dead, frontman Scott Lucas was informed by Island that the album needed to sell at least 100,000 copies for the band to remain with the label.
=== Metabolic === In acute hyperglycemia, ketoacidosis may develop because decreased insulin levels increase the activity of hormone sensitive lipase. The degradation of triacylglycerides by hormone-sensitive lipase produces free fatty acids that are eventually converted to acetyl-coA by beta-oxidation. Ketoacidosis is a life-threatening condition which requires immediate treatment. Symptoms include: shortness of breath, breath that smells fruity (such as pear drops), nausea and vomiting, and very dry mouth. Another life-threatening consequence of hyperglycemia is nonketotic hyperosmolar syndrome.
It contended that the benefits were substantial and that even if bacteria became resistant, new antibiotics would soon be developed, and there was no evidence that bacterial resistance in animals impacted human health. The Netherthorpe committee's conclusions were undermined by new research even before they were published, and the committee was recalled to reconsider the issue in 1965. New studies had shown that bacteria were not only able to inherit the genes for antibiotic resistance, but they could also communicate them to each other. In 1967, a multiresistant strain of E. coli killed fifteen children in the UK. The use of antibiotics in animals for nontherapeutic use was banned there in 1971. Many other European countries soon followed. When Sweden acceded to the European Union (EU) in 1995, a total ban on antibiotic growth promoters (AGPs) had been in place there for ten years. This would be superseded by more relaxed EU rules unless Sweden could demonstrate scientific evidence in favour of a ban. Two Swedish scientists, Anders Franklin and Christina Greko, and two Danish scientists, Frank Aarestrup and Henrik Wegener, took up the fight. The odds seemed against them but this coincided with the United Kingdom BSE outbreak, which resulted in intense political pressure. In December 1996, the European Parliament's Standing Committee on Health and Welfare voted to ban the use of AGPs. The EU went further and recommended broad restrictions on the use of antibiotics. These regulations were adopted in 2019 and took effect in 2022.
Sources: en.wikipedia.org
In the continental European countries occupied by the Axis powers, the native communist party usually led the armed resistance (guerrilla warfare and urban guerrilla warfare) against fascist military occupation. In Mediterranean Europe, the communist Yugoslav Partisans led by Josip Broz Tito effectively resisted the German Nazi and Italian Fascist occupation. In the 1943–1944 period, the Yugoslav Partisans liberated territories with Red Army assistance and established the communist political authority that became the Socialist Federal Republic of Yugoslavia. To end the Japanese occupation of China in continental Asia, Stalin ordered Mao Zedong and the Chinese Communist Party to temporarily cease the Chinese Civil War (1927–1949) against Chiang Kai-shek and the anti-communist Kuomintang as the Second United Front in the Second Sino-Japanese War (1937–1945). In 1943, the Red Army began to repel the Nazi invasion of the Soviet Union, especially at the Battle of Stalingrad (23 August 1942 – 2 February 1943) and at the Battle of Kursk (5 July – 23 August 1943). The Red Army then repelled the Nazi and Fascist occupation armies from Eastern Europe until the Red Army decisively defeated Nazi Germany in the Berlin Strategic Offensive Operation (16 April–2 May 1945). On concluding the Great Patriotic War (1941–1945), the Soviet Union was a military superpower with a say in determining the geopolitical order of the world.
== See also == Protein targeting Nervous system VGF Nerve Growth Factor-inducible, a protein whose expression is induced by NGF Neurotrophin Nerve growth factor receptor Growth factor Brain-derived neurotrophic factor
On the basis of these studies, as well as problems with allergies and clothing discoloration, PABA fell out of favor as a sunscreen. In 2008 it was banned as a sunscreen ingredient in the European Union and in 2019 the FDA proposed its limited use. However, water-insoluble PABA derivatives such as padimate O are currently used in some cosmetic products including mascara, concealer, and matte lipsticks. As of 2008, the advancement of new sunscreen is focused on developing a broad spectrum of active ingredients that provide consistent protection across all wavelengths, including UVA. Researchers are considering the PABA–TiO2 Hybrid Nanostructures that result from the method of aqueous in situ synthesis with PABA and TiO2.
=== Pyrimidines === Uridine phosphorylase or pyrimidine-nucleoside phosphorylase substitutes the anomeric-carbon-bonded phosphate of ribose 1-phosphate for the free base uracil, forming the nucleoside uridine. Uridine kinase (aka uridine–cytidine kinase) can then phosphorylate the 5’-carbon of this nucleoside into uridine monophosphate (UMP). UMP/CMP kinase (EC 2.7.4.14) can phosphorylate UMP into uridine diphosphate, which nucleoside diphosphate kinase can phosphorylate into uridine triphosphate. Thymidine phosphorylase or pyrimidine-nucleoside phosphorylase adds 2-deoxy-alpha-D-ribose 1-phosphate to thymine, with thymine bonding at the anomeric carbon of the deoxyribose, forming the deoxynucleoside thymidine. Thymidine kinase can then phosphorylate the 5’-carbon of this compound into thymidine monophosphate (TMP). Thymidylate kinase can phosphorylate TMP into thymidine diphosphate, which nucleoside diphosphate kinase can phosphorylate into thymidine triphosphate. The nucleosides cytidine and deoxycytidine can be salvaged along the uracil pathway by cytidine deaminase, which converts them to uridine and deoxyuridine, respectively. Alternatively, uridine–cytidine kinase can phosphorylate them into cytidine monophosphate (CMP) or deoxycytidine monophosphate (dCMP). UMP/CMP kinase can phosphorylate (d)CMP into cytidine diphosphate or deoxycytidine diphosphate, which nucleoside diphosphate kinase can phosphorylate into cytidine triphosphate or deoxycytidine triphosphate.
Sources: en.wikipedia.org
The Vanguard Group (8.97%) BlackRock (8.14%) State Street Corporation (4.26%) T. Rowe Price (3.92%) JPMorgan Chase (3.31%) Capital World Investors (2.93%) Fidelity Investments (2.49%) AllianceBernstein (2.23%) Geode Capital Management (2.11%) Pershing Square Capital Management (1.83%)
ASR-2001 (2CB-5PrO) is a propoxy TWEETIO and another notable analogue of 2C-B which is under development for treatment of psychiatric disorders. FLY derivatives of 2C-B like 2C-B-FLY, 2C-B-DRAGONFLY, and 2C-B-BUTTERFLY are analogues in which the methoxy groups of 2C-B on the phenyl ring have been cyclized into furan or other rings to form benzodifuran and other tricyclic compounds. 2-OH-2C-B is the 2-O-desmethylated analogue of 2C-B and shows similar potency as a serotonin 5-HT2A receptor agonist in vitro. Cyclized phenethylamine derivatives of 2C-B in which the side chain has been cyclized in some way include DOB-CR (2C-B-CR), 2CB-Ind, 2C-B-5-hemiFLY-α6 (BNAP), 2CB7 (2C-B-5-hemiFLY-β7), TCB-2 (2CBCB), 2C-B-PYR, 2C-B-3PIP, 2C-B-3PIP-NBOMe, 2C-B-3PIP-POMe, 2CBecca, 2CJP, 2CLisaB, ZC-B, 2C-B-aminorex (2C-B-AR), and 2C-B-morpholine (2C-B-MOR), among others. Other related cyclized compounds, while not technically phenethylamines or 2C-B derivatives, include 2C-B-BZP and 2C-B-PP. A notable positional isomer of 2C-B is the scaline and mescaline analogue 4-bromomescaline (4-Br-3,5-DMPEA). Deuterated isotopologues of 2C-B such as 2CB-2OCD3 (2-trideuteromethoxy-2C-B), 2CB-5OCD3 (5-trideuteromethoxy-2C-B), and hexadeutero-2C-B (2,5-di(trideuteromethoxy)-2C-B) among others have been described.
4-Chloromethcathinone (also known as 4-CMC and clephedrone) is a stimulant drug of the cathinone class that has been sold online as a designer drug. 4-CMC produces similar effects to mephedrone, and has been sold as an alternative in countries where mephedrone was scheduled. 4-CMC produces similar side effects to mephedrone, including: increased blood pressure, tachycardia, hyperthermia, and anxiety. Its chemical structure closely resembles para-chloromethamphetamine, raising concerns about its potential to readily induce cell death of serotonergic neurons. However, no neurotoxicity of this kind has been found to occur, but studies involving mice do indicate that it is neurotoxic through other mechanisms, similarly to other cathinones. 4-CMC is cytotoxic and induces oxidative stress, more so than 4-MMC. Moreover, β-keto substitution is thought to change cathinone structure activity relationships (SAR) and metabolism compared to amphetamines, leading to differences in pharmacology.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.